A key goal of heart failure (HF) management is to optimize patients' health status 1 -their symptoms, function, and quality of life. [2] [3] [4] Although prior studies have used HF-related morbidity and mortality to describe variations between healthcare systems (ie, resource utilization 5, 6 and patient volume 7 ) and providers, 8, 9 to date, there have been no studies describing health status differences across outpatient practices. Identifying practice-level differences in the successful management of patients' health status could provide novel insights into the current state of HF management across the United States and identify potential opportunities to improve care and patient-centered outcomes.
To address this gap in knowledge, we compared the health status of HF patients with reduced ejection fraction (HFrEF) across a heterogeneous sample of outpatient practice sites in the Change the Management of Patients With Heart Failure (CHAMP-HF) registry. 10 CHAMP-HF is a multicenter, prospective registry of outpatients with HFrEF that captures patients' health status using the short form of the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ)-12.
11 Importantly, as payers and other stakeholders begin to explore the use of patient-reported outcome (PRO) measures to measure providers' care quality, 12 it is essential to define the extent of health status variability and identify opportunities to improve clinical outcomes for patients with HFrEF, if such performance measures are to have the potential to improve care.
METHODS

Study Design
The data, methods used in the analysis, and materials used to conduct the research will not be made available to any researcher for purposes of reproducing the results or replicating the procedure. For this analysis, we used data from the CHAMP-HF registry: a prospective, observational study of outpatients with HFrEF at 149 US practice sites that has been described previously. 10 Patients eligible for enrollment met the following criteria: (1) age ≥18 years, (2) primary diagnosis of HFrEF (left ventricular ejection fraction ≤40% within 12 months of enrollment), (3) prescribed oral pharmacotherapy for HF at the time of enrollment, and (4) willingness to complete protocol requirements for study visits, procedures, and questionnaires. Patients were excluded if participating in any interventional clinical research study, receiving comfort care measures only or enrolled in a hospice program, had a life expectancy of <1 year, and had a history of, or planned, heart transplant, left ventricular assist device implantation, or dialysis. Data collected on enrollment included patient-level demographics and clinical characteristics, medical history, laboratory results, use of HF medications and devices, and patient-reported health status. Eligible sites were identified based on the completion of a feasibility survey, which provided investigators with the opportunity to ensure broad geographic and provider specialty representation. Study coordinators at each site were responsible for identification and enrollment of subjects during the course of a scheduled outpatient visit, with this analysis being limited to only those patients enrolled between December 2015 and March 2017. CHAMP-HF was sponsored by Novartis Pharmaceuticals Corporation, and all participating sites obtained local or central institutional review board approval before patient enrollment, as well as informed consent from each participant.
Data Collection
Site coordinators interviewed patients to collect their sociodemographic characteristics and health status while abstracting information from the medical record on medical history and medications at enrollment. Data collected from site feasibility surveys included practice specialty, annual patient volume, and availability of the following ancillary HF services: access to cardiac rehabilitation, dedicated HF clinic, multidisciplinary clinic, routine collection of PROs, and telemonitoring resources. The primary outcome for this cross-sectional analysis was the 12-item KCCQ Short Form (KCCQ-12) on enrollmenta reliable, sensitive, HF-specific PRO that measures patients' HF symptoms, physical and social limitations, and quality of life-that was completed by patients at each site through an electronic tablet. 11 The KCCQ-12 overall summary (OS) score and symptom frequency (SF) domain score were the primary outcomes for this study, to capture a summary of all clinically relevant HF domains (KCCQ-OS-the average of all 4 subscales) and symptoms alone (KCCQ-SF-the domain most likely to be optimized because of changes in diuretic and other cardiovascular therapies). Scores range from 0 to 100, where higher scores reflected better health status (fewer symptoms, fewer social or physical limitations, and better quality of life). A 5-point difference in KCCQ scores is considered to be clinically meaningful from both patients' and providers' perspectives. 13, 14 
Statistical Analysis
The enrollment characteristics of the CHAMP-HF cohort were assessed with descriptive statistics, using proportions for categorical variables and means with SDs or medians with quartiles
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for continuous variables. We used hierarchical logistic regression, with site as a random effect to account for clustering within sites, to identify site variability in achieving excellent health status or monthly to no symptoms. As a secondary analysis, to describe site characteristics associated with better health status (and the magnitude of these mean differences by KCCQ score), we added site characteristics as fixed effects to the hierarchical model. To describe site-level variability in health status across participating sites, we plotted the site-specific proportion of patients exhibiting baseline KCCQ-OS or KCCQ-SF scores of ≥75 with 95% confidence interval (CI). To quantify the magnitude of these differences, we then calculated an adjusted median odds ratio (aMOR), 15 which estimates the median relative difference in 2 statistically identical patients having excellent health status or monthly to no symptoms when receiving treatment at 2 random sites within the CHAMP-HF registry. Finally, we used multivariable logistic regression to examine the proportional change in site-level variance after sequential adjustment for (1) patient, (2) patient and treatment, and (3) patient, treatment, and site characteristics for both KCCQ-OS and KCCQ-SF scores. For each sequential model, we obtained an estimate of the random site effect variance on the log-odds scale. The incremental proportional change in variance was calculated as proportional change in variance=(Va−Vb)/Va, where Va represents the variance of the prior model and Vb, the variance of the model with added covariates. To better quantify the differences across practices as a secondary analysis, we constructed adjusted linear regression analyses to more accurately describe the mean differences in KCCQ scores explained by site characteristics.
Our regression models accounted for 34 patient and treatment characteristics previously shown to be significant, 16 where patient characteristics included sociodemographics (age, sex, ethnicity, and race), socioeconomic status (employment status, insurance provider, highest level of education, and total annual household income), clinical comorbidities (body mass index, atrial fibrillation, chronic obstructive lung disease, chronic kidney disease, coronary disease, depression, diabetes mellitus, hypertension, hyperlipidemia, and smoking status), and HF severity (systolic blood pressure, pulse, left ventricular ejection fraction, history of ventricular arrhythmias, and number of hospitalizations in the prior 12 months). Additionally, 11 HFrEF treatment characteristics (cardiac resynchronization therapy, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, angiotensin-neprilysin inhibitor, mineralocorticoid receptor blocker, hydralazine, loop diuretic, digoxin, ivabradine, inotrope, and total number of HF therapies) were included. Nonlinear variables were handled by fitting piecewise linear splines. To examine the association between site characteristics and mean health status differences by KCCQ scores, we added 7 practice characteristics: annual HF patient volume, access to cardiac rehabilitation, access to telemonitoring services, dedicated HF clinic, physician specialty, routine use of PROs, and location (urban, suburban, or rural).
Rates of missing data for patient-level variables, overall, were small (<8%), except for household income (≈24% of patients). We applied multiple imputation to impute missing values of each variable. Five imputations were created using fully conditional specification method. The results across 5 imputed data sets were then combined by averaging, and SEs were adjusted to reflect both within-imputation variability and between-imputation variability. All estimates were reported using 95% CIs, and a P value ≤0.05 was considered statistically significant. All analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC). Analyses were performed independently by the Duke Clinical Research Institute, and the lead author takes responsibility for guiding data analysis and interpretation.
RESULTS
A total of 3552 patients were enrolled across 149 outpatient practice sites in the CHAMP-HF registry. After excluding patients who were ineligible per the study protocol (n=34) and those with missing KCCQ-12 (n=14) or sociodemographic (n=10) data, 3494 were included in the final analyses ( Figure 1 ). Baseline patient characteristics are described in Table 1 .
Site Characteristics and Patient Health Status Distributions
The characteristics of all enrolling practice sites are described in Table 2 . Most sites were general cardiology practices (60.9%), followed by HF specialists (23.1%), internal medicine (7.8%), and family medicine (6.3%) practices. The majority of sites offered 
Health Status Variability Across Sites-aMOR
The proportion of CHAMP-HF patients at each site that had KCCQ-OS or KCCQ-SF scores ≥75 are shown in Figures 2 and 3 , respectively. There was a wide range in the proportion of patients with excellent health status (0%-77%) and monthly or fewer symptoms (8%-82%). The aMOR across sites was large, after adjusting for 24 patient and treatment characteristics, suggesting substantial variability across sites. For overall health status (KCCQ-OS), the aMOR was 1.70 (95% CI, 1.54-1.99; P<0.001) indicating an average 70% (95% CI, 54%-99%) higher odds of having excellent health status if the same patient was treated at 1 random site versus another (P<0.0001). For good-to-excellent symptom control, the aMOR was 1.54 (95% CI, 1.41-1.76) indicating that for any 2 randomly selected practices, the median odds that a patient would have minimal symptoms was 54% (95% CI, 41%-76%) higher at 1 site versus another (P=0.001). Site variability was substantially reduced after adjusting for patient characteristics (proportional change in variance, 38.9%). However, subsequent adjustments were not associated with further reductions (proportional change in variance of −2.9% with the addition of medical therapies and −0.2% with added site characteristics). A different pattern was seen for KCCQ-SF, where adjustment for patient characteristics reduced observed variability by 21%; no further reduction was observed after adjusting for medical ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid antagonist; VF, ventricular fibrillation; and VT, ventricular tachycardia.
*Emergency medicine/urgent care. therapies, and an incremental 23.5% reduction was observed with the addition of site characteristics.
Differences in Health Status by Site Characteristics-Fully Adjusted Linear Regression Models
Marked site-level differences were observed, by KCCQ-OS score, in fully adjusted linear regression analyses. Compared with patients enrolled at family practices, those at HF (+6.5 points; 95% CI, 0.5-12.4; P=0.033) and general cardiology (+6.5 points; 95% CI, 1.4-11.7; P=0.012) practices had significantly higher scores, whereas those enrolled at internal medicine (+3.7; 95% CI, −2.3 to 9.7; P=0.228) clinics had similar scores. Patients enrolled at a suburban setting, also, had higher health status compared with those at an urban setting (+3.2; 95% CI, 0.2-6.1; P=0.034). There were no other practice characteristics associated with patients' health status (Table 3) . Similar findings were observed for KCCQ-SF assessments where, compared with patients treated by family practices, those treated at HF (+5.4 points; 95% CI, −1.0 to +11.9; P=0.10), general cardiology (+5.0 points; 95% CI, −0.5 to +10.6; P=0.074), and internal medicine (+5.4 points; 95% CI, −1.0 to +11.9; P=0.10) practices had a nonstatistically significant trend for fewer symptoms. Those enrolled at a suburban setting had significantly better symptom control than those treated in an urban setting (+3.3; 95% CI, +0.1 to +6.4; P=0.043).
DISCUSSION
Examining health status variability across practices is an important next step to establishing the suitability of PROs for quality assessment, as currently being developed by the Centers for Medicare and Medicaid Services and for defining the potential to improve patient-centered outcomes. This is the first study, of which we are aware, to ever examine the outpatient practice variability in health status and symptom control. Substantial practice-level differences highlighted a potential opportunity for improvement, which persisted after adjustment for numerous patient and treatment characteristics-and where patient characteristics were the most important in explaining the unadjusted variation in practices' mean KCCQ scores. We found that, after full adjustment, there was a 70% median odds of a statistically identical patient having excellent health status at 1 random practice versus another and a 54% difference in average likelihood of having minimal symptoms. Identifying and disseminating the management styles of high-performing practices has the potential to reduce practice variability and improve the symptoms, function, and quality of life of outpatients with HFrEF. Moreover, our study results emphasize the potential of a PRObased performance measure to incentivize practices to optimize the health status of their patients with HFrEF in the outpatient setting, 17 which can complement current efforts focusing on inpatient and early postdischarge outcomes.
Our findings extend prior studies' descriptions of specialty-level differences in cardiovascular outcomes in patients with HFrEF. However, although those analyses focused on traditional end points, including guideline- directed medical therapy, 18 hospitalization, 19 and mortality, 20, 21 we found substantial variations in patientreported health status-an evolving benchmark of patient care. Nonetheless, although our findings suggest that patients treated by cardiovascular providers were more likely to experience better health status as compared with those treated by primary practitioners, future studies are needed to better understand the subtleties of clinical practice, regardless of specialty, associated with optimizing patients' health status. 22 The discovery that patients enrolled and treated at suburban, as opposed to urban or rural, settings exhibit improved health status is not novel. However, our work extends prior studies' reporting on patient access to healthcare and hospitalization rates across developed settings 23 to that of health status. The finding that patients receiving care at suburban practices demonstrated better quality of life is logical given our current understanding of the positive relationship between socioeconomic status and HF-related quality of life. [24] [25] [26] [27] Importantly, these health status differences remained after adjusting for multiple indicators of patient socioeconomic status.
Our findings must be interpreted in context of the following limitations. First, although CHAMP-HF represents one of the largest registries capturing diseasespecific health status of patients with HFrEF in routine clinical care, it was conducted in voluntary participating sites committed to clinical research and might, therefore, not be fully generalizable to the entire country. Second, although patients were enrolled at a singular designated clinic, it was not recorded whether they received care from other providers in regard to their HF management. However, the fact that our findings were comparable to other specialty-level differences in HFrEF outcomes supports our findings. Third, our analysis was cross-sectional, and further work to address patients' health status trajectories over time, and whether site-level variability in titration of medical therapies contributes to health status differences, is needed. Moreover, we were unable to collect the duration or frequency by which a patient had been seen by a provider and whether there was a difference in the duration of care across clinics that might have influenced our findings. Fourth, the associations we observed might have been influenced by residual measured or unmeasured confounders. Some may think that we should not have adjusted for treatment because that is one of the key mediators of health status benefit, but including these adjustments underscored the magnitude of variability and the need to better understand such variations (including whether the doses and tailoring of treatments are optimal). Finally, this analysis was not able to formally test mediators of observed difference in health status across vulnerable groups or define practice patterns to reduce these disparities. This is particularly relevant in that we know that, overall, the routine collection of PROs was 30.2% but do not know what PROs were routinely used in the practices or whether the patients with the greatest potential to benefit from telemonitoring or cardiac rehabilitation services were receiving these therapies. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin-receptor neprilysin inhibitor; CI, confidence interval; HF, heart failure; PRO, patient-reported outcome measures; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire Overall Summary; and KCCQ-SF, Kansas City Cardiomyopathy Questionnaire Symptom Frequency. *Model variables: age, sex, race, ethnicity, body mass index, total annual household income, employment status, chronic obstructive lung disease, chronic kidney disease, depression, atrial fibrillation, number of prior heart failure hospitalizations within prior 12 mo, pulse, left ventricular ejection fraction, ACEi/ARB, ARNI, loop diuretic, physician specialty, number of patients with heart failure managed annually, access to cardiac rehabilitation, dedicated heart failure clinic, routine collection of PROs, availability of telemonitoring resources, and patient population.
†Emergency medicine/urgent care.
CONCLUSIONS
In leveraging data from a unique, observational registry of stable outpatients with HFrEF, we found substantial site-level variability in patients having excellent health status or monthly to no symptoms. These findings support the use of PROs as a measure of healthcare quality in HFrEF and inform the need to develop novel strategies to improve patient outcomes, thereby reducing differences in outpatient care quality.
